By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Company, Ltd. 

4-6-10 Koishikawa, Bunkyo-ku

Tokyo    112-8088  Japan
Phone: 81-3-3817-3700 Fax: n/a


SEARCH JOBS


Key Statistics


Email: webmaster@eisai.co.jp
Ownership: Public

Web Site: Eisai Company
Employees: 7,043
Symbol: ESALY.PK
 









Company News
Eisai Company (ESALY.PK) Release: FYCOMPA (perampanel) CIII Demonstrates A Significant Reduction In Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency In Phase 3 Trial Of Patients With Epilepsy Age 12 And Older 8/24/2015 7:36:03 AM
Eisai Company (ESALY.PK) Employees Will Be Offered Biogen (BIIB) Jobs When RTP Campus Ownership Deal Closes 7/16/2015 7:30:31 AM
ASCO15: Eisai Company (ESALY.PK)'s Eribulin Extends Survival in Patients With Rare Cancers 6/1/2015 6:21:20 AM
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015 10:49:00 AM
Battling U.S. Market Headwinds, Eisai Company (ESALY.PK) Cuts 200+ Jobs 4/10/2015 6:00:24 AM
Epizyme (EPZM) Reacquires Rights to Cancer Drug From Eisai Company (ESALY.PK) in Deal Worth $110 Million 3/12/2015 6:22:50 AM
Eisai Company, Ltd. (ESALY.PK) And Merck & Co. (MRK) Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer 3/5/2015 11:23:24 AM
FDA Approves Eisai Company (ESALY.PK)'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer 2/16/2015 10:23:14 AM
Eisai Company, Ltd. (ESALY.PK)'s Thyroid Drug Snags Early FDA Approval 2/13/2015 9:55:14 AM
Eisai Company, Ltd. (ESALY.PK) Announces Top-Line Results Of Investigational Study On Coadministration Of Lorcaserin And Phentermine 12/1/2014 7:16:54 AM
12345678910...
//-->